Benutzer: Gast  Login
Titel:

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.

Dokumenttyp:
Article; Clinical Trial, Phase III; Randomized Controlled Trial; Journal Article
Autor(en):
Weller, J; Schäfer, N; Schaub, C; Tzaridis, T; Zeyen, T; Schneider, M; Potthoff, A L; Giordano, F A; Steinbach, J P; Zeiner, P S; Kowalski, T; Sabel, M; Hau, P; Krex, D; Grauer, O; Goldbrunner, R; Schnell, O; Tabatabai, G; Ringel, F; Schmidt-Graf, F; Brehmer, S; Tonn, J C; Bullinger, L; Vajkoczy, P; Glas, M; Vatter, H; Herrlinger, U; Seidel, C
Abstract:
PURPOSE: In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity. Here, we analyze high grade hematotoxicity and its prognostic relevance in the trial population. METHODS: Descriptive and comparative analysis of hematotoxicity adverse events ≥ grade 3 (HAE) according to the Common Terminology of Clinical Adverse Events, version 4.0 was...     »
Zeitschriftentitel:
J Neurooncol
Jahr:
2023
Band / Volume:
161
Heft / Issue:
1
Seitenangaben Beitrag:
147-153
Volltext / DOI:
doi:10.1007/s11060-022-04203-4
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/36609807
Print-ISSN:
0167-594X
TUM Einrichtung:
1411; 1533; Klinik und Poliklinik für Neurologie (Prof. Hemmer)
 BibTeX